請由右方點選想進一步了解的主題
了解費森尤斯卡比到2026年有甚麼計畫
費森尤斯卡比的過去以及現在發展
企業社會責任
請由右方點選想進一步了解的產品類別
生物相似藥
醫療儀器
靜脈注射藥品
癌症用藥
腎臟營養
週邊靜脈營養
腸道營養
在找工作嗎?歡迎加入我們
For us, integrity means doing the right thing – by fostering a culture of accountability and transparency within our company and with our partners.
在此閱讀費森尤斯卡比的相關新聞、最新消息或動人故事分享。
Q3/2025: Strong organic revenue and excellent EPS growth; EBIT growth guidance raised
Explore how biosimilars drive smarter healthcare investment and global access with Fresenius Kabi’s support for Biosimilars Week 2025.
Recognized by Vizient for supply assurance and strategic collaboration, Fresenius Kabi earns two major awards.
Dr. Hannah Wozniak receives €250,000 JUMPstart Clinical Nutrition research award for a personalized nutrition and early mobilization trial in ventilated patients.
Fresenius continues to reduce complexity and increase efficiency in its global network. In line with #FutureFresenius, the company announces the divestment of Fresenius Kabi’s Calea homecare business in Canada.
Fresenius is collaborating with other companies and academic institutions with the goals of accelerating the manufacturing of CAR-T cell therapy, making it more cost-effective, and improving patient access across Europe.
Q2/2025: Ongoing strong revenue and EPS growth, guidance for organic revenue growth raised
Fresenius Kabi will exclusively commercialize Polpharma Biologics’ vedolizumab biosimilar candidate PB016 globally (except in the Middle East and North Africa).
Fresenius announced that the European Commission has granted approval for their denosumab biosimilars Conexxence®* and Bomyntra®* in Europe.
Dr. Wan Daud from Malaysia receives €100,000 research support through the JUMPstart Renal Nutrition Therapy Program to conduct her CKD nutrition study.
Recognized for service and innovation, Fresenius Kabi earns its 5th Premier award. Discover how we help hospitals improve care and reduce costs.
NutriKabina by Fresenius Kabi is a telehealth innovation that enables fast, accessible nutrition screening for oncology patients in hospitals across Argentina.
Fresenius Kabi advances responsible antibiotic manufacturing with AMR certification at its Portugal site: protecting public health for future generations.
mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce that the European Commission has granted approval for its denosumab biosimilars Denbrayce® and Izamby®.
Fresenius Kabi’s fifth and sixth biosimilars Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) are now available in the U.S. for all approved indications for their respective reference products, Prolia® (denosumab) and Xgeva® (denosumab).
Discover how Fresenius Kabi is expanding global R&D centers for Nutrition. Explore the new locations driving excellence.
Fresenius announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for the marketing authorization of its biosimilar candidates to Prolia® (denosumab) and Xgeva® (denosumab).
Q1/2025: Strong top line and excellent EPS growth, outlook confirmed
Discover best practices in perioperative nutrition from leading surgical experts. Four podcast episodes on surgery and nutrition management.
Lizl Veldsman from South Africa wins the award for her study on preventing muscle loss in ICU patients, supported by Fresenius Kabi's research grant.
Fresenius Kabi optimizes production network: Fresenius Kabi and EMS have signed an agreement to transfer the ownership of Fresenius Kabi's production site in Anápolis, Brazil, to EMS.
Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence®** (denosumab-bnht) and Bomyntra®** (denosumab-bnht) of its operating company Fresenius Kabi has been approved by the FDA.
We were honored to welcome over 100 healthcare professionals from 33 countries to our headquarters for the FRANC2024 Oncology – the Fresenius Kabi Advanced Nutrition Conference.
Learn more about chronic kidney disease and how health care professionals play a crucial role in early detection and patient education.
Fresenius Kabi’s ustekinumab biosimilar Otulfi® (ustekinumab-aauz), developed by Formycon AG, is now available in the United States and European Union.
FY/24: Upgraded outlook achieved, consistent financial performance with profitable growth.
With this mentoring program, Fresenius Kabi supports early-career clinicians and researchers through education, networking, and funding opportunities.
To further advance research and medical education in the field of intensive care medicine, Fresenius Kabi continues its collaboration with ESICM in 2025.
Fresenius, via its operating company Fresenius Kabi, announced today that the U.S. FDA has granted 510(k) clearance to its Adaptive Nomogram.
Fresenius Kabi is a Top Employer in 2025, with twelve countries receiving certification from the Top Employers Institute.
Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm (SCD).
Fresenius, through its operating company Fresenius Kabi, announced today that Epinephrine Injection, USP, is now available in the United States.
Search
搜尋
醫療器材
衛署醫器輸字第023778號
如要查看產品詳細內容，請點下方按鈕